Analytical Data
-
Gene name
MLLT3
- Application
-
Alternative Names
ALL1-fused gene from chromosome 9 protein Myeloid/lymphoid or mixed-lineage leukemia translocated to chromosome 3 protein YEATS domain-containing protein 3
-
Species
Human
-
Source
E. coli
-
Tag
N- His-B2M
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P42568
-
Expression Region
1-568aa
-
Molecular Weight
77.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MLLT3, or Mixed-Lineage Leukemia Translocation Protein 3, serves as a significant protein implicated in the pathogenesis of various hematological malignancies, particularly acute myeloid leukemia (AML). This protein is known for its role in chromosomal translocations, specifically the t(11;19)(q23;p13) translocation that results in its fusion with the ENL or other partner genes, leading to aberrant gene expression and contributing to oncogenesis. Research has shown that MLLT3 interacts with components of the transcriptional machinery, thereby influencing hematopoietic differentiation and cellular proliferation. Given its critical involvement in cancer biology, MLLT3 has garnered attention as a potential therapeutic target. Studies on the recombinant form of MLLT3 are crucial for understanding its structure-function relationship, elucidating its role in gene regulation, and developing inhibitors that could mitigate its oncogenic effects. Furthermore, the production of recombinant MLLT3 facilitates biophysical and biochemical characterization, providing insights that might lead to innovative treatment strategies for patients suffering from MLLT3-related malignancies. Overall, the exploration of MLLT3 serves not only to deepen our understanding of its biological functions but also to pave the way for novel therapeutic interventions in the fight against cancer.
